Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil
pharmaphorum is proud to announce its inaugural “The World Without Disease Summit”: a high quality, two-day event bringing together key global leaders and innovators to explore the potentia
The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), seeking approval of talqueta
Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac
People whose blood pressure remains stubbornly high despite current drug treatment and are at increased risk of complications such as kidney disease and stroke could have another treatment
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change